NSE: AUROPHARMA· HealthCareValue · Aug 26Mid cap
Aurobindo Pharma
Value: largest US ANDA portfolio
- Last close
- ₹1,697.70
- 29 Sept 2026 · reference
- 1D · 1M
- 0.0% · +3.2%
- price-only
- Weight
- 1.6%
- 31 Jul 2026 · Aug rank 29
- Thesis review
- 8 Sep 2026
- Why We Own, p42
Where the price sits
52-week range, house target and street targets
52w low ₹1,07152w high ₹1,734
- Reference close₹1,698
- Axis Securities · HOLD₹1,600
Range from reference closes; street targets from the PDFs on file (Research & documents). Internal target is never shown to prospects.
Investment case and valuation
Approved model, 8 Sep 2026 review
₹1,658
Price (2026-09-07)
26.0x / 20.2x
FY27E / FY28E P/E (Buoyant sheet)
10.5%
FY27E ROE (Buoyant sheet)
25.2x
Trailing P/E
2.5x
Price / book
21%
EPS CAGR FY26–28E
TTM PE 25.2x per screener; 5-yr average PE not sourced. Axis notes it raised target multiple from 17x to 18x, i.e. stock is at the upper end of its own recent range after +58% in 12 months. EV/EBITDA computed as mcap/FY26 EBITDA given net-cash position. EV/EBITDA 13.9x; dividend yield 0.2%.
- Model date
- 8 Sep 2026 (prices 7–8 Sep 2026)
- Horizon
- 12 months (bank pages: Sep-2027 roll-forward)
- Audience
- Internal — the book's guardrail: do not quote a target to a client; quote the thesis and the risk
- Reviewer · version
- Investment Committee framework · v1 (book)
Current vs history
Trailing multiples, FY-end
| Ratio | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E | 17.2x | 13.5x | 19.5x | 8.5x | 9.7x | 14.8x | 15.8x | 20.1x | 19.3x | 21.6x |
| Price to Book | 4.2x | 2.8x | 3.3x | 1.4x | 2.4x | 1.6x | 1.1x | 2.1x | 2.1x | 2.0x |
Tijori FY-end multiples on reported earnings/book; compatible definitions across years, but not the same basis as Buoyant's forward P/E on internal EPS.
UnavailableScenario lab disabled. Needs an approved forward EPS and forward P/E for Aurobindo Pharma plus a reference price. Missing inputs are not substituted.